Instil Bio, Inc. Stock Price, News & Analysis

Instil Bio (Nasdaq: TIL) reported Q3 2025 results and a corporate update on Nov 13, 2025.

Key points: $83.4 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments as of Sep 30, 2025 versus $115.1 million as of Dec 31, 2024; company expects these resources to fund operations beyond 2026. Axion Bio, a subsidiary, dosed the first patient in a Phase 1 monotherapy trial of AXN-2510/IMM2510 in Oct 2025; collaborator ImmuneOnco presented updated relapsed/refractory squamous NSCLC data at WCLC 2025.

Selected financials: Q3 2025 net loss per share was $2.01 (GAAP) and non-GAAP net loss per share was $1.75; nine-month GAAP net loss per share was $9.53.

Instil Bio (NASDAQ:TIL) announced that ImmuneOnco presented promising preliminary data for their '2510 therapy in treating squamous non-small cell lung cancer (sq-NSCLC) at the 2025 World Conference on Lung Cancer. The Phase 1 study showed an objective response rate (ORR) of 35.3% in 17 evaluable patients who had previously failed PD-(L)1 inhibitor and platinum-doublet chemotherapy.

The study evaluated different dose levels (3, 6, 10, or 20 mg/kg Q2W), with most patients receiving the 20 mg/kg Q2W dose. The therapy demonstrated efficacy across PD-L1 TPS scores, with majority of responses in negative and low PD-L1 TPS scores. The treatment was generally well-tolerated, with mainly manageable low-grade infusion reactions and two Grade 3 VEGF-related adverse events.

Instil Bio (Nasdaq: TIL) reported its Q2 2025 financial results and corporate updates. The company achieved significant milestones including FDA clearance of the IND application for AXN-2510/IMM2510 in July, with U.S. clinical trial initiation expected by end of 2025. The company appointed Jamie Freedman, M.D., Ph.D., as Chief Medical Officer in June.

Financial position remains strong with $103.6 million in total cash and investments as of June 30, 2025, expected to fund operations beyond 2026. Q2 2025 saw increased R&D expenses of $6.7 million and in-process R&D expenses of $10.0 million. The company reported a non-GAAP net loss per share of $2.88 for Q2 2025.

Instil Bio (NASDAQ:TIL) and ImmuneOnco reported promising preliminary data from a Phase 2 trial of IMM2510/AXN-2510, their PD-L1xVEGF bispecific antibody, combined with chemotherapy for front-line non-small cell lung cancer (NSCLC) patients in China.

The trial showed significant efficacy with partial responses in 62% of evaluable patients, including 80% response rate in squamous NSCLC and 46% in non-squamous NSCLC patients. Among 33 patients treated at 10 mg/kg, the drug demonstrated a favorable safety profile with no dose-limiting toxicities and minimal serious adverse events.

The company plans to advance the drug to Phase 3 studies and initiate a US Phase 1 trial by the end of 2025.

Instil Bio (NASDAQ: TIL) has received FDA clearance for its Investigational New Drug (IND) application for AXN-2510, a PD-L1xVEGF bispecific antibody. The company plans to initiate a Phase 1 trial for relapsed/refractory solid tumors by the end of 2025.

The Phase 1 trial will evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics of AXN-2510 as monotherapy. Additionally, ImmuneOnco is expected to share initial safety and efficacy results from an ongoing Phase 2 study of AXN-2510 combined with chemotherapy in first-line NSCLC in China during the second half of 2025.

Instil Bio (NASDAQ: TIL) has appointed Dr. John Maraganore to the Board of Directors of its subsidiary Axion Bio, which is developing AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors with a focus on first-line non-small cell lung cancer (NSCLC). Dr. Maraganore, the founding CEO of Alnylam Pharmaceuticals, brings over 30 years of biotechnology experience and was instrumental in developing RNA interference (RNAi) into a validated therapeutic approach. The appointment comes as ImmuneOnco's Phase 2 trial of AXN-2510 combined with chemotherapy for first-line NSCLC approaches completion of enrollment this summer. The company believes AXN-2510 has shown promising early safety and efficacy data and could potentially become a best-in-class treatment for solid tumors.

Instil Bio (Nasdaq: TIL) has appointed Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman, a Hematologist-Oncologist with over 20 years of leadership experience in biopharma drug development, will focus on advancing AXN-2510, a PD-L1xVEGF bispecific therapy for solid tumors. His impressive track record includes 15 drug approvals across multiple therapeutic areas and executive roles at major pharmaceutical companies including Genentech, AstraZeneca, GSK, and Merck. Dr. Freedman holds M.D. and Ph.D. degrees from Tufts University and completed training at UCSF and Harvard. He maintains an active clinical practice at the UCSF VA Medical Center and has pioneered inclusive trials for underserved patients.

Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical company developing novel therapies, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Bronson Crouch will deliver a presentation on Thursday, June 5, 2025, at 4:20 PM ET. Interested parties can access a live webcast of the presentation through the provided weblink. This conference participation represents an opportunity for Instil Bio to showcase its pipeline and developments to the investment community.

Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) announced they will co-host an investor and analyst breakfast event in Chicago on May 31, 2025. The event, scheduled from 8:00 to 9:30 am CT near McCormick Convention Center, will feature company management and a key opinion leader in immuno-oncology. They will discuss the PD-(L)1xVEGF bispecific antibody landscape and provide clinical trial updates. Interested investors and analysts can register by emailing investorrelations@instilbio.com.